• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exploring the effect of roxadustat on oxidative stress: a pilot-exploratory study in CKD patients using a molecular biology approach.

作者信息

Cacciapuoti Martina, Makoudjou Pulcherie Ghislaine, Driussi Giulia, Caputo Ilaria, Basso Anna, Calò Lorenzo A, Nalesso Federico

机构信息

Nephrology, Dialysis and Transplantation Unit, Department of Medicine (DIMED), University of Padua and Padua University Hospital, Via Giustiniani 2, 35128, Padua, Italy.

Nephrology Unit, Santa Maria della Misericordia Hospital, Rovigo, Italy.

出版信息

J Nephrol. 2025 Aug 23. doi: 10.1007/s40620-025-02393-4.

DOI:10.1007/s40620-025-02393-4
PMID:40848221
Abstract
摘要

相似文献

1
Exploring the effect of roxadustat on oxidative stress: a pilot-exploratory study in CKD patients using a molecular biology approach.探索罗沙司他对氧化应激的影响：一项使用分子生物学方法对慢性肾脏病患者进行的初步探索性研究。
J Nephrol. 2025 Aug 23. doi: 10.1007/s40620-025-02393-4.
2
Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.C反应蛋白对罗沙司他治疗慢性肾脏病贫血疗效的影响：随机对照试验的系统评价
BMC Nephrol. 2024 Feb 5;25(1):47. doi: 10.1186/s12882-024-03474-5.
3
Efficacy of Roxadustat in Anemia with Chronic Kidney Disease.罗沙司他治疗慢性肾脏病贫血的疗效
Curr Pharm Des. 2025;31(22):1816-1822. doi: 10.2174/0113816128354065250114154721.
4
Long-term safety and effectiveness of roxadustat in Chinese patients with chronic kidney disease-associated anemia: The ROXSTAR registry.罗沙司他在中国慢性肾脏病相关性贫血患者中的长期安全性和有效性：ROXSTAR注册研究
Chin Med J (Engl). 2025 Jun 20;138(12):1465-1476. doi: 10.1097/CM9.0000000000003672. Epub 2025 May 29.
5
Explore the effect of HIF-PHI on blood pressure variation rate and anemia efficacy in maintenance hemodialysis patients.探讨缺氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHI）对维持性血液透析患者血压变异性及贫血疗效的影响。
BMC Nephrol. 2025 May 29;26(1):267. doi: 10.1186/s12882-024-03928-w.
6
Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.罗沙司他治疗透析依赖和非透析依赖慢性肾脏病患者贫血的疗效与安全性：一项系统评价和荟萃分析
Br J Clin Pharmacol. 2022 Mar;88(3):919-932. doi: 10.1111/bcp.15055. Epub 2021 Sep 30.
7
Cardiorenal Interorgan Assessment via a Novel Clustering Method Using Dynamic Time Warping on Electrocardiogram: Model Development and Validation Study.通过一种基于心电图动态时间规整的新型聚类方法进行的心肾器官间评估：模型开发与验证研究
JMIR Med Inform. 2025 Aug 12;13:e73353. doi: 10.2196/73353.
8
Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他（FG-4592）可减少 Dahl 盐敏感性大鼠的肾纤维化。
J Hypertens. 2024 Mar 1;42(3):497-505. doi: 10.1097/HJH.0000000000003623. Epub 2023 Nov 27.
9
Ratings of parenting stress in mild to moderate chronic kidney disease in children: a pilot investigation.儿童轻度至中度慢性肾病中父母压力的评分：一项初步调查。
Pediatr Nephrol. 2025 Sep 2. doi: 10.1007/s00467-025-06936-6.
10
Antioxidants for adults with chronic kidney disease.抗氧化剂治疗慢性肾脏病成人患者。
Cochrane Database Syst Rev. 2023 Nov 2;11(11):CD008176. doi: 10.1002/14651858.CD008176.pub3.

本文引用的文献

1
Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease.接受罗沙司他治疗慢性肾脏病贫血患者的铁参数
J Clin Med. 2023 Jun 22;12(13):4217. doi: 10.3390/jcm12134217.
2
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.慢性肾脏病新型贫血治疗方法：改善全球肾脏病预后组织（KDIGO）争议会议的结论。
Kidney Int. 2023 Oct;104(4):655-680. doi: 10.1016/j.kint.2023.05.009. Epub 2023 May 24.
3
Novel function of Roxadustat (FG-4592) as an anti-shock drug in sepsis by regulating mitochondrial oxidative stress and energy metabolism.
罗沙司他（FG-4592）通过调节线粒体氧化应激和能量代谢发挥抗休克药物的新功能，可用于脓毒症。
Biochim Biophys Acta Gen Subj. 2023 Jan;1867(1):130264. doi: 10.1016/j.bbagen.2022.130264. Epub 2022 Oct 21.
4
Pathomechanism of oxidative stress in cardiovascularrenal remodeling and therapeutic strategies.心血管肾脏重塑中氧化应激的病理机制及治疗策略
Kidney Res Clin Pract. 2022 Sep;41(5):533-544. doi: 10.23876/j.krcp.22.069. Epub 2022 Sep 30.
5
Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.罗沙司他通过靶向血管紧张素受体和 eNOS 预防 Ang II 型高血压。
JCI Insight. 2021 Sep 22;6(18):e133690. doi: 10.1172/jci.insight.133690.
6
Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.抗贫血药物 FG4592 通过改善血管再生和抗氧化能力来延缓 AKI 向 CKD 的转变。
Clin Sci (Lond). 2021 Jul 30;135(14):1707-1726. doi: 10.1042/CS20210100.
7
ROCK (RhoA/Rho Kinase) in Cardiovascular-Renal Pathophysiology: A Review of New Advancements.RhoA/ROCK激酶在心血管-肾脏病理生理学中的研究进展综述
J Clin Med. 2020 May 2;9(5):1328. doi: 10.3390/jcm9051328.
8
Oxidative stress - chronic kidney disease - cardiovascular disease: A vicious circle.氧化应激 - 慢性肾脏病 - 心血管疾病：恶性循环。
Life Sci. 2018 Oct 1;210:125-131. doi: 10.1016/j.lfs.2018.08.067. Epub 2018 Aug 31.
9
Effect of excess iron on oxidative stress and gluconeogenesis through hepcidin during mitochondrial dysfunction.线粒体功能障碍期间，过量铁通过铁调素对氧化应激和糖异生的影响。
J Nutr Biochem. 2015 Dec;26(12):1414-23. doi: 10.1016/j.jnutbio.2015.07.008. Epub 2015 Jul 29.